Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

ANTA PHAR
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -37,1 M
Net income 2017 -31,2 M
Debt 2017 -
Yield 2017 -
Sales 2018 8,47 M
EBIT 2018 -40,7 M
Net income 2018 -40,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 2,42x
Capitalization 20,5 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases.It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
04:20p ANTHERA PHARMACEUTICALS : Announces Positive Outcome of Interim Futility Analysi..
12/11 Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analys..
11/21 ANTHERA PHARMACEUTICALS : Announces Receipt of Nasdaq Listing Determination Noti..
11/20 ANTHERA PHARMACEUTICALS,INC. (NASDAQ : ANTH) Files An 8-K Notice of Delisting or..
11/17 ANTHERA PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Contin..
11/17 Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Not..
11/10 ANTHERA PHARMACEUTICALS : Announces Completion of Recruitment in the Phase 3 RES..
11/09 Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RE..
11/08 ANTHERA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
11/06 ANTHERA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
More news
Sector news : Bio Therapeutic Drugs
04:24p France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 5
Average target price 6,80 $
Spread / Average Target 359%
EPS Revisions
Managers
NameTitle
John Craig Thompson President, CEO & Executive Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
William R. Shanahan Chief Medical Officer
David E. Thompson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR22
GILEAD SCIENCES3.64%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS94.94%35 831
GENMAB0.85%11 452
BLUEBIRD BIO INC177.39%9 249